Moderna to Open mRNA Manufacturing Facility in Kenya

The $500 million state-of-the-art site will produce up to 500 million vaccine doses a year.

The global pandemic turned Moderna into a household name as one of the primary COVID-19 vaccine manufacturers. Now, according to a recent FiercePharma article, the company is investing $500 million in a manufacturing facility in Kenya. First announced in October of 2021, the site will focus on the production of up to 500 million vaccines a year. In the future, the site could expand to include fill-finish and packaging capabilities under the same roof. Though the exact location and size of the facility have yet to be disclosed, the company is planning to have the site built and operational by 2023.

More in Quick Hits